Healthcare & Life Sciences Blog -

Healthcare & Life Sciences Supply Chains Series: Achieving Stability Through Innovation and Compliance (3 of 4)

by Cecilia Pastor, Melissa K. Allchin, Indradeep Bhattacharya, Carolina Pardo, Jaspreet Takhar and Lip Kian Ang

Healthcare Services

The U.S. Department of Health and Human Services Issues Favorable Opinion on Healthcare Company’s Donations to Charitable Foundation

by Lois Sheng Liu and Xin Tao

Medical Devices

Medical Devices and In Vitro Diagnostic Regulations: Brussels Signals It’s Ready to Cut Red Tape?

by Jaspreet Takhar and Julia Gillert

Medical Devices

Healthcare & Life Sciences Supply Chains Series: Trade Winds, Tariffs, and Optimizing Operations (2 of 4)

by Cecilia Pastor, Kerry B. Contini, Daniel Garcia, Els Janssens, Julia Skubis Weber, Anastasia Herasimovich, Xin Tao, Celeste Ang and Henrique K. Frizzo

Medical Devices

The MHRA’s Summer Glow-Up: UK Medical Device Laws Get a Makeover

by Jaspreet Takhar, Elina Angeloudi and Julia Gillert

Healthcare & Life Sciences Supply Chains Series: Achieving Stability Through Innovation and Compliance (3 of 4)

Medical Devices August 15, 2025

Healthcare & Life Sciences Supply Chains Series: Strategic Decisions for Business Continuity (1 of 4)

The healthcare and life sciences sector is facing new trade winds and a looming threat of increased tariffs. This places additional pressure on a…

Pharmaceuticals & Biotech July 28, 2025

EU and German Courts Clarify Rules on Rx Drug Discounts in latest DocMorris decisions

With its ruling in Apothekerkammer Nordrhein v. DocMorris (Case C-517/23), the Court of Justice of the European Union (CJEU) provided further clarity on the…

Medical Devices July 17, 2025

Mitigating Risk in Life Sciences Acquisitions

In the race to innovate, life sciences companies are betting big on M&A, but navigating the risks requires smarter deal structures Big pharmaceutical companies…

EU Pharmaceutical Package

In EU Pharmaceutical Package

A New Dawn for the EU Pharma Regulatory Regime? The Commission’s Proposal to Revise the EU Pharmaceutical Legislation is Finally Published

April 26, 2023 by Els Janssens, Magda Tovar and Julia Gillert 5 Mins Read

Today the European Commission has finally published its Proposal to revise the EU Pharmaceutical legislation, the most momentous…

In EU Pharmaceutical Package

EU Pharma Package: How Significant are the Proposals for Orphan Medicines?

May 16, 2023 by Els Janssens, Magda Tovar and Julia Gillert 6 Mins Read

On 26 April 2023 the European Commission published its Proposals to Reform the EU pharmaceutical legislation.[1] We continue…

In EU Pharmaceutical Package

Hungarian Pricing and Reimbursement Reforms Aiming to Remove Hurdles to Late Market Access of Innovative Pharmaceuticals

May 26, 2023 by Dr. Helga Bíró M.Jur. and Máté Laczkó 3 Mins Read

In brief Reimbursing medicinal products is critical to ensure that treatments are widely available to patients. This is…

In EU Pharmaceutical Package

The EU Pharmaceutical Package From a National Perspective: Member States’ First Reactions

May 30, 2023 by Els Janssens, Julie Yeni, Dr. Martin Altschwager LL.M., Dr. Frank Pflueger and Magda Tovar 6 Mins Read

The Proposal to revise the EU Pharmaceutical legislation has generated unprecedented levels of attention, not only across the…

In EU Pharmaceutical Package

The Future is Green: Eco Measures are Embedded into the EU Reform Proposals

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 2 Mins Read

As previously covered in this blog, on 26 April 2023 the European Commission published a set of proposals…

In EU Pharmaceutical Package

Supply Chain Protection: What do the EU Reform Proposals Look Like and do They go Far Enough?

June 13, 2023 by Julia Gillert, Els Janssens and Magda Tovar 3 Mins Read

As already well noted on this blog, on 26 April 2023 the European Commission published a set of…